Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.60 |
| ▸ | RECQL | P46063 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 5/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.60 |
| ▸ | CDK2 | P24941 | 4/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7643991 | 0.89 | MEN1 (0.58) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL925356 | 0.88 | MEN1 (0.57) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| SCHEMBL926285 | 0.88 | MAPT (0.67) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| SCHEMBL17786621 | 0.86 | ACHE (0.55) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| SCHEMBL5126244 | 0.85 | KDM4E (0.64) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| SCHEMBL7658406 | 0.85 | KDM4E (0.62) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| SCHEMBL17786624 | 0.85 | MAPT (0.52) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| SCHEMBL17786494 | 0.84 | MAPT (0.69) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| SCHEMBL7664503 | 0.84 | KDM4E (0.61) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| SCHEMBL7652753 | 0.84 | MEN1 (0.55) | MEN1KMT2AKDM4EMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742033-B1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | ARMARON BIO PTY LTD (AU) | 2018-09-19 | — | — | EP | claimed |
| US-20140275156-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2014-09-18 | — | — | US | claimed |
| EP-2742033-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | Neuprotect PTY Ltd (AU) | 2014-06-18 | — | — | EP | claimed |
| WO-2013020184-A9 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2013-04-18 | — | — | WO | claimed |
| WO-2013020184-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2013-02-14 | — | — | WO | claimed |
| EP-1109800-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LIMITED (KR) | 2001-06-27 | — | — | EP | claimed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | claimed |
| EP-2742033-B1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | ARMARON BIO PTY LTD (AU) | 2018-09-19 | — | — | EP | disclosed |
| US-20140275156-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2014-09-18 | — | — | US | disclosed |
| EP-2742033-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | Neuprotect PTY Ltd (AU) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013020184-A9 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013020184-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2013-02-14 | — | — | WO | disclosed |
| US-6500846-B1 | 2-(4-CHLOROPHENYL)-7-METHOXYCHROMEN-4-ONE, AS CYCLIN-DEPENDENT KINASE INHIBITORS, USED AS ANTICARCINOGENIC AGENTS OR FOR PROPHYLAXIS OF NEURODEGENERATIVE DISEASE | LG CHEMICAL, LTD. (KR) | 2002-12-31 | — | — | US | disclosed |
| EP-1109800-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LIMITED (KR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275156-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | BAX, MAPKAPK2, MAPK6 | MEN1 4291/4885KMT2A 4574/4885KDM4E 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.